相关实验视频
Updated: Sep 13, 2025

07:54
Cholesterol Efflux Assay
Published on: March 6, 2012
30.0K
埃泽蒂米布可降低2型糖尿病中的α-托科菲罗尔水平
A Toffalini1, N Vigolo, N Rolli
1Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Hospital Trust of Verona, Verona, Italy. giacomo.zoppini@univr.it.
European review for medical and pharmacological sciences
|August 1, 2025
概括
在2型糖尿病患者中,以泽提治疗可通过抑制其通过尼曼-皮克C1类蛋白质吸收而显著降低血中α-托科菲罗尔水平. 这一发现凸显了这种常见药物治疗患者的潜在营养影响.
科学领域:
- 内分泌学 在内分泌学.
- 营养科学 营养科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔法-托科菲罗尔 (维生素E) 保护免受自由基的破坏.
- 尼曼-皮克C1-like 1 (NPC1L1) 蛋白质促进了alpha-tocopherol的肠道吸收.
- 埃泽提米布向NPC1L1,通常用于治疗高胆固醇血症,通常与他类药物一起,用于2型糖尿病患者.
研究的目的:
- 对2型糖尿病患者的血α-托哥菲罗尔水平对以泽蒂治疗的影响进行调查.
- 为了确定以泽提米布是否会影响血中α-托科菲罗尔度.
主要方法:
- 招募了200名没有服用维生素补充剂的2型糖尿病患者.
- 使用高性能液体染色学 (HPLC) 测量阿尔法-托科菲罗尔.
- 利用线性多变量回归来分析与α-托科菲罗尔水平相关的因素,比较以泽胺使用者和非使用者.
主要成果:
- 与非使用者 (32.9 ± 7.0 μmol/L; p=0.006) 相比,接受埃泽蒂米布的患者表现出显著较低的血α-托哥法醇平均水平 (29.9 ± 5.7 μmol/L).
- 在多变量分析 (β = -0.217,p = 0.002) 中,以泽提治疗与α-托科菲罗尔水平呈现出显著的负相关性.
结论:
- 埃泽蒂米布治疗可以降低血α-托哥菲罗尔水平.
- 这种减少可能是由于ezetimibe对NPC1L1蛋白的抑制,NPC1L1蛋白对alpha-tocopherol吸收至关重要.
- 需要进一步的研究,以了解在服用ezetimibe的患者中降低的α-托科菲罗尔的临床意义.
相关概念视频
Atherosclerosis III: Management
35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
875
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
875
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
263
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
263
Cholesterol: Significance and Regulation
689
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
689
Oral Hypoglycemic Agents: Biguanides and Glitazones
304
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
304
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
888
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
888

